Drugs News and Research

RSS

African first ladies gather to discuss HIV/AIDS

On the sidelines of the African Union Summit in Addis Ababa, Ethiopia, on Monday, the General Assembly of the Organization of African First Ladies Against HIV/AIDS (OAFLA) gathered to discuss the continent's progress against HIV/AIDS, Walta Info reports.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Chronic inflammation has been directly associated with heart disease and other physical ailments. But LSU graduate student Nathanial Gilbert and Professor of Biological Sciences Marcia Newcomer, together with Associate Professor Sue Bartlett, have developed the first 3-D model of Human 5-Lipoxygenase, or 5-LOX, the molecule responsible for creating inflammatory compounds that provoke asthma.

3 Feb 2011

Malarial drugs may help treat specific form of frontotemporal dementia

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain, which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin.

3 Feb 2011

Poor adolescents with strong community get protection from risky health behaviors

Children who grow up in poverty have health problems as adults. But a new study finds that poor adolescents who live in communities with more social cohesiveness and control get some measure of protection; they're less likely to smoke and be obese as adolescents.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

New study examines role of later acquisition of hepatitis C in HIV patients

Hepatitis C is a leading cause of illness and death for individuals infected with both HIV and hepatitis C. Recent reports from around the world demonstrate that hepatitis C is emerging as a sexually transmitted infection among HIV-infected men who do not inject drugs. However, many HIV-infected men do not receive continued screening for hepatitis C throughout their HIV care.

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

The launch of the International Genomics of Alzheimer's Project (IGAP) - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease - was announced today by a multi-national group of researchers including Drs. Lindsay Farrer and Sudha Seshadri at Boston University School of Medicine (BUSM). The collaborative effort, spanning universities from both sides of the Atlantic, will combine the knowledge, staff and resources of four consortia that work on Alzheimer's disease genetics.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

$Researchers find breast cancer therapy contributes to early-in-life hip fractures in women$

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

A hip fracture is not common in a 54-year-old woman, unless she is a 54-year-old breast cancer survivor, according to a new Northwestern Medicine study. Researchers found that a combination of early menopause due to breast cancer treatment and common drugs used to treat breast cancer, could be weakening the bones of breast cancer survivors once they hit middle age, leading to hip fractures.

2 Feb 2011

Drugs affecting brain noradrenaline levels could improve breathing in sleep apnea patients

New research from the University of Toronto could provide some restful nights for the 18 million North Americans who suffer from obstructive sleep apnea.

2 Feb 2011

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Today Quebec is providing access to a therapy in a new class of osteoporosis treatments. With Quebec being the first province to list Prolia on public and private drug plans, Canadians living with osteoporosis in the province of Quebec now have access to increased treatment options.

2 Feb 2011

Research discovers new role of TRPV1 receptors in regulation of locomotor activity

Research by a Barrow Neurological Institute scientist on the thermoregulatory effects of a receptor more commonly studied for its role in pain is the cover story in the Feb. 2 issue of the Journal of Neuroscience.

2 Feb 2011

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.

1 Feb 2011

FDA approves NCI's Sodium Fluoride F18 NDA for use in bone scans

The FDA has approved a New Drug Application from the National Cancer Institute, part of the National Institutes of Health, for a new strength of a previously approved drug, Sodium Fluoride F18, for use in bone scans.

1 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Drugs News and Research

African first ladies gather to discuss HIV/AIDS

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Malarial drugs may help treat specific form of frontotemporal dementia

Poor adolescents with strong community get protection from risky health behaviors

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

New study examines role of later acquisition of hepatitis C in HIV patients

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

Drugs affecting brain noradrenaline levels could improve breathing in sleep apnea patients

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Research discovers new role of TRPV1 receptors in regulation of locomotor activity

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

FDA approves NCI's Sodium Fluoride F18 NDA for use in bone scans

OPKO Health acquires CURNA

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News